Related Experiment Video
Updated: Feb 9, 2026

Purification of Ubiquitinated p53 Proteins from Mammalian Cells
Published on: March 21, 2022
Highly Potent Clickable Probe for Cellular Imaging of MDM2 and Assessing Dynamic Responses to MDM2-p53 Inhibition
Honorine Lebraud1, Richard A Noble2, Nicole Phillips2
1Astex Pharmaceuticals , 436 Cambridge Science Park , Cambridge CB4 0QA , United Kingdom.
Abstract:
MDM2 is a key negative regulator of the p53 tumor suppressor. Direct binding of MDM2 to p53 represses the protein's transcriptional activity and induces its polyubiquitination, targeting it for degradation by the proteasome. Consequently, small molecule inhibitors that antagonize MDM2-p53 binding, such as RG7388, have progressed into clinical development aiming to reactivate p53 function in TP53 wild-type tumors. Here, we describe the design, synthesis, and biological evaluation of a trans-cyclooctene tagged derivative of RG7388, RG7388-TCO, which showed high cellular potency and specificity for MDM2. The in-cell reaction of RG7388-TCO with a tetrazine-tagged BODIPY dye enabled fluorescence imaging of endogenous MDM2 in SJSA-1 and T778 tumor cells. RG7388-TCO was also used to pull down MDM2 by reaction with tetrazine-tagged agarose beads in SJSA-1 lysates. The data presented show that RG733-TCO enables precise imaging of MDM2 in cells and can permit a relative assessment of target engagement and MDM2-p53 antagonism in vitro.
Insights
Researchers developed RG7388-TCO, a novel molecule targeting MDM2, a key regulator of the p53 tumor suppressor. This tool allows for precise imaging and assessment of MDM2 engagement in cancer cells.
Area of Science:
- Oncology
- Molecular Biology
- Chemical Biology
Background:
- MDM2 is a critical negative regulator of the p53 tumor suppressor protein.
- MDM2 inhibition is a therapeutic strategy for TP53 wild-type tumors.
- RG7388 is a small molecule inhibitor of MDM2-p53 binding in clinical development.
Purpose of the Study:
- To design, synthesize, and evaluate RG7388-TCO, a trans-cyclooctene tagged derivative of RG7388.
- To utilize RG7388-TCO for imaging endogenous MDM2 in cancer cells.
- To assess RG7388-TCO's utility in evaluating MDM2-p53 antagonism.
Main Methods:
- Synthesis of RG7388-TCO, a functionalized MDM2 inhibitor.
- Bioorthogonal chemistry: click reaction between trans-cyclooctene (TCO) and tetrazine.
- Fluorescence imaging of endogenous MDM2 using tetrazine-BODIPY dye.
- Affinity pull-down assay using tetrazine-agarose beads.
Main Results:
- RG7388-TCO demonstrated high cellular potency and specificity for MDM2.
- Successful in-cell fluorescence imaging of endogenous MDM2 in SJSA-1 and T778 tumor cells.
- RG7388-TCO enabled pull-down of MDM2 from cell lysates.
- The compound facilitates assessment of target engagement and MDM2-p53 antagonism.
Conclusions:
- RG7388-TCO is a valuable chemical biology tool for MDM2 research.
- This derivative enables precise visualization and quantification of MDM2 activity in vitro.
- RG7388-TCO supports the development of MDM2-targeted cancer therapies.
Related Concept Videos
Inflammatory Response I: Vascular and Cellular
Feedback Inhibition
Dynamic Equilibrium
Enzyme Inhibition
Inhibition of Cdk Activity
Responses to Gravity and Touch

